Twinbeech Capital LP Sells 54,091 Shares of LivaNova PLC (NASDAQ:LIVN)

Twinbeech Capital LP lowered its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 91.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,204 shares of the company's stock after selling 54,091 shares during the quarter. Twinbeech Capital LP's holdings in LivaNova were worth $241,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Two Sigma Advisers LP lifted its position in LivaNova by 148.5% in the 4th quarter. Two Sigma Advisers LP now owns 214,545 shares of the company's stock worth $9,936,000 after buying an additional 128,200 shares during the last quarter. Two Sigma Investments LP increased its stake in LivaNova by 27.2% in the 4th quarter. Two Sigma Investments LP now owns 439,582 shares of the company's stock worth $20,357,000 after purchasing an additional 93,985 shares during the period. Sherbrooke Park Advisers LLC purchased a new position in LivaNova in the 4th quarter worth approximately $378,000. Royal Bank of Canada increased its stake in LivaNova by 8.0% in the 4th quarter. Royal Bank of Canada now owns 361,356 shares of the company's stock worth $16,733,000 after purchasing an additional 26,790 shares during the period. Finally, Redmile Group LLC increased its stake in LivaNova by 19.3% in the 4th quarter. Redmile Group LLC now owns 1,043,539 shares of the company's stock worth $48,326,000 after purchasing an additional 168,500 shares during the period. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on LIVN shares. Mizuho reduced their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group reduced their price target on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Robert W. Baird boosted their target price on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Barclays dropped their target price on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $64.00 target price on shares of LivaNova in a report on Tuesday, May 13th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $59.29.

LivaNova Stock Performance

Shares of NASDAQ:LIVN traded up $0.39 during midday trading on Thursday, reaching $43.18. 175,202 shares of the company's stock traded hands, compared to its average volume of 650,066. The company has a market cap of $2.35 billion, a price-to-earnings ratio of 102.58 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a one year low of $32.48 and a one year high of $61.94. The stock has a 50 day moving average of $38.93 and a 200 day moving average of $44.47.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.